Clinical trials: Crohn Disease (CD)
Crohn's Disease
Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.
Crohn's disease (CD) is an incurable chronic inflammatory disorder of the gastrointestinal tract. This study will assess how safe and effective upadacitinib is in treating moderately to severely active CD in real world.
- Trial name
- UPlift (NCT05930275)
- Where
- 180 sites in Australia, Bulgaria and 15 more
- Volunteers
- 1,200 people
- Sponsor
- AbbVie
Crohns Disease
A Study to Evaluate the Effect of Fecal Transplant and Dietary Changes on Disease Activity in Patients With Crohn Disease on Advanced Therapies
Advanced therapies including biologics and small molecules target specific inflammatory pathways. IBD's multifactorial etiology means that blocking a single pathway may not be sufficient for all patients.
- Trial name
- BOOST-CD (NCT06890637)
- Testing
- Fecal Microbial Transplantation, Crohns Disease Exclusion Diet, Advanced therapy
- Where
- 6 sites in India
- Volunteers
- 168 people
- Sponsor
- All India Institute of Medical Sciences
Crohn's Disease, Inflammatory Bowel Disease
An Open Label Safety and Tolerability Study of AIN457 in Patients With Moderate to Severe Crohn's Disease
This study will assess the safety and tolerability of AIN457 in patients with moderate to severe Crohn's disease who already participated and completed the core trial CAIN457A2202.
- Trial name
- NCT01009281
- Testing
- AIN457
- Where
- 5 sites in United States
- Volunteers
- 7 people
- Sponsor
- Novartis Pharmaceuticals
Crohn's Disease
A Study of Subcutaneous HUMIRA (Adalimumab) Injection to Assess Adverse Events and Change in Disease Activity In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)
Crohn's disease (CD) is an incurable chronic inflammatory disorder of the gastrointestinal tract. This study will assess how safe and effective Humira (adalimumab) is in treating moderately to severely active CD in China.
- Trial name
- NCT05394805
- Where
- 10 sites in China
- Volunteers
- 156 people
- Sponsor
- AbbVie
Inflammatory Bowel Diseases (IBD), Crohn Disease (CD)
NORDTREAT Prospective Study on Inflammatory Bowel Disease
Inflammatory bowel disease (IBD), primarily ulcerative colitis (UC) and Crohn's disease (CD), is a chronic disease entity affecting individuals of all ages, and which may severely impact the lives of the patients and their…
- Conditions
- Inflammatory Bowel Diseases (IBD), Crohn Disease (CD), Ulcerative Colitis (UC)
- Trial name
- NCT05414578
- Where
- 17 sites in Denmark, Iceland and 2 more
- Volunteers
- 366 people
- Sponsor
- University of Southern Denmark
Crohn Disease (CD), Ulcerative Colitis (UC)
Leucine-rich α2-glycoprotein Correlation With Clinical, Endoscopic and Histological Disease Activity of IBD in a EuRopean Context
Prospectively study the correlation between Leucine-rich α2-glycoprotein (LRG) and clinical/endoscopic/histological disease activity in patients with inflammatory bowel disease (IBD) in Europe.
- Trial name
- LEADER (NCT07621783)
- Testing
- Leucine-rich α2-glycoprotein
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Imelda GI Clinical Research Center
Crohn's Disease (CD)
Unraveling the Blood Microbiome in Postoperative Recurrence of Crohn's Disease
Crohn's disease, a chronic inflammation of the gastro-intestinal tract, is a disease with a complex pathogenetic background. Hereditary factors, environmental factors and the gut flora play a varying role in its onset, however…
- Trial name
- IBDbloom (NCT06770140)
- Where
- Netherlands
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Erasmus Medical Center
Crohn's Disease
Efficacy and Safety of Formulation Switching Between SC Infliximab and IV Infliximab in Patients With CD
The goal of this prospective, multicenter, open-label, randomized controlled, non-inferiority trial is to test efficacy and safety of formulation switching between subcutaneous (SC) infliximab and intravenous (IV) infliximab in…
- Trial name
- CHAMELEON (NCT06064864)
- Testing
- Infliximab-Dyyb
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Asan Medical Center
Crohn Disease
Clinical Study Comparing PillCam® Crohn's Capsule Endoscopy to Ileocolonoscopy (IC) Plus MRE for Detection of Active CD in the Small Bowel and Colon in Subjects With Known CD and Mucosal Disease.
This study will evaluate the efficacy of capsule endoscopy (CE) versus ileocolonoscopy (IC) plus MRE for detection of active Crohn's disease (CD) in the small bowel in subjects with known CD and mucosal disease.
- Trial name
- BLINK (NCT03241368)
- Testing
- Capsule Endoscopy
- Where
- 26 sites in United States, Austria and 1 more
- Volunteers
- 187 people
- Sponsor
- Medtronic - MITG
Pediatric Crohn's Disease
Post-Marketing Surveillance of Humira in Korean Pediatric Crohn's Disease (CD) Patients Under the "New-Drug Re-examination"
This study is a non-interventional, observational study of Humira® in the treatment of pediatric CD as per the New Drug Re-examination Guideline in Korea.
- Trial name
- NCT02578238
- Volunteers
- 143 people
- Sponsor
- AbbVie
Crohn Disease
Reverse-Engineering of Exclusive Enteral Nutrition (RE-EEN) in Crohn's Disease: A Multi-Center Trial
This study will compare the tolerability and efficacy of conventional formula Exclusive Enteral Nutrition (EEN) and whole-food blended smoothie EEN by enrolling a total of 60 participants with newly diagnosed pediatric Crohn's…
- Trial name
- mRE-EEN (NCT06216899)
- Testing
- Whole-food based smoothie, Formula
- Where
- 3 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- Seattle Children's Hospital
Crohn Disease of Intestine
MILESTONE-CD -A Prospective Multiomic Inception Real -Life Study To Evaluate Predictors of Disease Outcomes & respoNse to Biologic Treatment in Crohn's Disease
Crohn's' disease (CD) is a lifelong-chronic inflammatory condition of the digestive tract. CD frequently manifests during the 2nd or 3rd decade; prolonged disease duration frequently results in major structural complications such…
- Trial name
- MILESTONE-CD (NCT04612621)
- Testing
- combination of diagnostic tests
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Sheba Medical Center
Crohn Disease (CD)
Comparison Between Artificial Intelligence and Standard Reading to Investigate Suspected Crohn Disease: the SCAI STUDY
The diagnosis of Crohn's Disease (CD) is based on a combination of clinical, biochemical (serological and fecal), endoscopic, radiological, and histological investigations.
- Trial name
- SCAI (NCT07111715)
- Testing
- Small bowel Video Capsule Endoscopy (VCE) using an Capsule System equipped with a Deep Neural Network based system called SmartScan (SC),
- Where
- Italy
- Volunteers
- 180 people
- Sponsor
- Fondazione Poliambulanza Istituto Ospedaliero
Crohn Disease (CD)
Impact of Advanced Crohn's Disease Therapies on Sleep Quality
The goal of this observational study is to measure changes in sleep quality before and after starting treatment with advance therapy in adult with Crohn disease.
- Trial name
- NCT07649408
- Testing
- Wearable activity and sleep tracker
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Shmuel Kivity, MD
Crohn's Disease, Ulcerative Colitis
Predicting Response to Vedolizumab in Pediatric Inflammatory Bowel Diseases
Vedolizumab (VDZ) is a humanized immunoglobulin G1 monoclonal antibody acting against α4β7 integrin which modulates lymphocyte trafficking in the gut.
- Conditions
- Crohn's Disease, Ulcerative Colitis, Inflammatory Bowel Disease
- Trial name
- NCT02862132
- Testing
- Vedolizumab
- Where
- 15 sites in United States, Denmark and 4 more
- Volunteers
- 142 people
- Sponsor
- Shaare Zedek Medical Center
Crohn's Disease (CD), Ulcerative Colitis (UC)
Supplementation of Vitamin D3 in Patients With Inflammatory Bowel Diseases and Hypovitaminosis D
This study aims to evaluate the effect of vitamin D3 supplementation on disease activity and quality of life in IBD patients deficient in vitamin D, and also help determine the optimal dose of vitamin D3 for them.
- Trial name
- NCT01877577
- Testing
- Vitamin D3
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, San Francisco
Inflammatory Bowel Disease (Crohn's Disease; Ulcerative Colitis), NON-IBD
AI-Enhanced Wide-Field Endoscopic Fluorescence Mapping of Gastrointestinal Mucosal Permeability in IBD - A Pilot Study in IBD Patients and Controls
This pilot study will test a new imaging system that uses fluorescent dye and artificial intelligence (AI) during colonoscopy to measure how "leaky" the lining of the colon is in people with inflammatory bowel disease (IBD).
- Trial name
- NCT07546955
- Testing
- Artificial Intelligence-Enhanced Wide-Field Mucosal Permeability Mapping
- Volunteers
- 70 people
- Sponsor
- Hamilton Health Sciences Corporation
Crohn Disease, Rectal Fistula
A Study Using Artificial Intelligence to Identify Adults With Complex Perianal Fistulas Associated With Crohn's Disease
Natural Language Processing and machine learning are examples of artificial intelligence tools. This study will check if these tools correctly identify people with Crohn's disease with complex perianal fistulas from their medical…
- Trial name
- INTUITION-CPF (NCT04844593)
- Where
- 3 sites in Spain
- Volunteers
- 32 people
- Sponsor
- Takeda
Crohn's Disease, IBD
An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease
This study seeks to evaluate the safety and efficacy of brazikumab versus placebo (Stage I) and versus an active comparator (Stage 2) in participants with moderately to severely active CD and will include assessments of clinical…
- Trial name
- INTREPID (NCT03759288)
- Testing
- Brazikumab low dose, Brazikumab high dose, Humira®
- Where
- 102 sites in United States, Canada and 15 more
- Volunteers
- 89 people
- Sponsor
- AstraZeneca
IBD (Inflammatory Bowel Disease), Crohn Disease (CD)
Individualizing Anti-TNF Therapy in Patients With Inflammatory Bowel Disease
This observational study aims to identify genes that may affect how patients with inflammatory bowel disease respond to anti-TNF treatment and why some patients lose response to treatment over time.
- Conditions
- IBD (Inflammatory Bowel Disease), Crohn Disease (CD), Ulcerative Colitis (UC)
- Trial name
- NCT07644117
- Testing
- This is an observational study with no intervention. Patients will receive anti- TNF therapy as part of their standard care
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Shmuel Kivity, MD